Atea Pharmaceuticals Inc. (AVIR)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Atea Pharmaceuticals, Inc. (AVIR) Q4 2024 Earnings Call Transcript
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR ) Q4 2024 Earnings Conference Call March 6, 2025 4:30 PM ET Company Participants Jonae Barnes - Senior Vice President, Investor Relations & Corporate Communications Jean-Pierre Sommadossi - Chief Executive Officer & Founder Janet Hammond - Chief Development Officer Arantxa Horga - Chief Medical Officer Andrea Corcoran - Chief Financial Officer & Executive Vice President, Legal Conference Call Participants Bella Camaj - JPMorgan Andy Hsieh - William Blair Operator Good afternoon, everyone, and welcome to the Atea Pharmaceuticals' Fourth Quarter 2024 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode.
After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study
On Wednesday, Atea Pharmaceuticals, Inc. AVIR released Phase 2 study data from the regimen of bemnifosbuvir and ruzasvir for the hepatitis C virus infection that causes liver swelling and can lead to serious liver damage.
Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year?
Here is how Atea Pharmaceuticals, Inc. (AVIR) and Butterfly Network, Inc. (BFLY) have performed compared to their sector so far this year.
Atea Pharmaceuticals, Inc. (AVIR) Q3 2024 Earnings Call Transcript
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR ) Q3 2024 Results Conference Call November 7, 2024 4:30 PM ET Company Participants Jonae Barnes - SVP of Investor Relations and Corporate Communications Dr. Jean-Pierre Sommadossi - Founder, Chairman and Chief Executive Officer Dr. Janet Hammond - Chief Development Officer John Vavricka - Chief Commercial Officer Dr. Arantxa Horga - Chief Medical Officer Andrea Corcoran - Chief Financial Officer and Executive Vice President of Legal Conference Call Participants Isabella Camaj - JPMorgan Andy Hsieh - William Blair Operator Good afternoon, everyone, and welcome to the Atea Pharmaceuticals Third Quarter 2024 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode.
Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?
Here is how Atea Pharmaceuticals, Inc. (AVIR) and Doximity (DOCS) have performed compared to their sector so far this year.
New Strong Buy Stocks for October 16th
CLPR, REE, HMY, AVIR and WPRT have been added to the Zacks Rank #1 (Strong Buy) List on October 16, 2024.
Atea Pharmaceuticals (AVIR) Loses -8.01% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Atea Pharmaceuticals (AVIR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year?
Here is how Atea Pharmaceuticals, Inc. (AVIR) and PetIQ (PETQ) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?
Here is how Atea Pharmaceuticals, Inc. (AVIR) and McKesson (MCK) have performed compared to their sector so far this year.
All You Need to Know About Atea Pharmaceuticals (AVIR) Rating Upgrade to Buy
Atea Pharmaceuticals (AVIR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year?
Here is how Atea Pharmaceuticals, Inc. (AVIR) and Novo Nordisk (NVO) have performed compared to their sector so far this year.
Atea Pharmaceuticals, Inc. (AVIR) Q2 2024 Earnings Call Transcript
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR ) Q2 2024 Results Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Jonae Barnes - Senior Vice President of Investor Relations and Corporate Communications Jean-Pierre Sommadossi - Founder, Chairman and Chief Executive Officer Arantxa Horga - Chief Medical Officer Janet Hammond - Chief Development Officer John Vavricka - Chief Commercial Officer Andrea Corcoran - Chief Financial Officer and Executive Vice President of Legal Conference Call Participants Maxwell Skor - Morgan Stanley Jonathan Miller - Evercore ISI Operator Good afternoon, everyone, and welcome to the Atea Pharmaceuticals Second Quarter 2024 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode.
